Markham & Read Announces $600,000 Federal Jury Award to Orange County Businessman Bruce Cahill Following Verdict of Fraud and Libel against Paul P. Edalat
Boston-based law firm Markham & Read today announced that in the case of Bruce Cahill et. al. versus Paul Pejman Edalat et. al. (U.S. Federal Court Docket: 8:16-cv-00686), a federal jury has determined that Edalat deliberately acted with oppression, fraud or malice toward Cahill, the former CEO by of Pharma Pak, Inc. who claimed Edalat had launched a smear campaign against him on social media over a year-long period.
The jury issued an award of $600,000 in damages suffered by Cahill and ruled that Edalat is liable for punitive damages. A hearing will take place in U.S. District Court, Central District of California (Santa Ana division) on August 22nd to determine the extent of punitive damages.
The jury also found that Edalat was liable for damages to Pharma Pak investors Greg Cullen, Ron Franco and Shane Scott.
“We are pleased that the jury sent a clear message to Paul Edalat while fully supporting Bruce Cahill and his longstanding good reputation in the community,” said John J. Markham, attorney for Cahill and the Pharma Pak investors. “The verdict and resulting damages are proof positive that Mr. Cahill was completely vindicated against Edalat’s unscrupulous actions and defamatory statements, along with others who the jury determined were damaged by Edalat.”
During the trial, Markham and attorney Bridget A. Zerner set forth evidence and testimony showing that Edalat induced more than $4 million of investment into Pharma Pak from Cahill, Cullen, Franco, Scott and others by making numerous claims regarding the company’s value, its intellectual property, its existing customer base and roster of prospective clients.
Throughout the proceedings, jurors heard direct evidence that Edalat, an Orange County native who previously filed bankruptcy in Southern California (U.S. Bankruptcy Court Docket: 8:14-bk-14529-TA) and in 2014 was “permanently restrained and enjoined … from directly or indirectly manufacturing, preparing, packing, labeling, holding, or distributing any dietary supplements” by the U.S. District Court for the Central District of California (U.S. Federal Court Docket: SACV 14-01759-JLS), used investment money to pay for gambling debts in Las Vegas and other lavish expenses. They also reviewed many postings Edalat made on social media regarding the former Pharma Pak CEO’s personal life, which formed the basis of Mr. Cahill’s claims in court that Edalat sought to defame him after litigation was filed in federal court.
Further, the jury ruled that Edalat’s co-defendant, Olivia Karpinski, was liable for $11,000 in damages to Cahill based on defamatory claims she made on social media.
During the trial, the jury heard the testimony of an Irvine police officer that discredited Karpinski’s attempt to falsely claim that she was a victim of sexual battery. Karpinski went to the Irvine Police Department on October 13, 2016, the day before she was deposed in the case and filed a report (Irvine CA Police Department Record #16-15720) claiming she was the victim of “stalking” and returned to the station two hours later to make an additional claim of sexual battery. According to the report, the officer explained her account was not sexual battery and questioned why she waited 11 months to report the allegations. Karpinski had previously posted the false battery claims against Cahill on her Instagram account, where they remained visible to the public for several months.
“As an entrepreneur and philanthropist in Southern California for over 30 years, I am grateful that the jury acknowledged my reputation as an honest, successful businessman in sectors such as technology, semiconductors, publishing, and real estate industries,” said Cahill. “I’m also pleased that they recognized the damages caused by the numerous false claims and defamatory statements made against me by Paul Edalat.”
Scott Farmelant/Jill Reilly
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Sunny Optics Officially Licenses ImmerVision Panomorph Lens Technology for Global Production13.12.2017 12:47 | Pressemelding
ImmerVision, developer of exclusive and patented panomorph wide-angle imaging technology, is proud to announce that Sunny Optics (Zhongshan) Co., a subsidiary of Sunny Optical Technology (Group) Co. Ltd., a leading manufacturer of integrated optical components and products, has licensed panomorph lens technology for global production, and will deliver its first small form-factor panomorph high-resolution super-wide-angle lenses for smartphones and mobile devices in Q1 2018. Panomorph lens technology combines state-of-the-art optical design and advanced, optimized algorithms, including low-power dewarping, to produce high-resolution super-wide-angle images without distortion, even in low light conditions. Sunny Optical is the largest Chinese lens supplier for the most popular smartphone brands and OEM applications such as sports cameras, surveillance, 360 image capture, autom
Synacor Launches Enhancements to Zimbra Communications and Collaboration Suite13.12.2017 12:30 | Pressemelding
Synacor Inc. (NASDAQ:SYNC) today announced the commercial launch of Zimbra 8.8. The easy-to-use collaboration platform comes with new user experience features such as Zimbra Drive for enterprise-level file sync and sharing and Zimbra Chat. The Network Edition features tech stack enhancements including real-time backup, ActiveSync across mobile and desktop, hierarchical storage management (HSM) that enables customers to move archival data to less expensive storage solutions, and improved delegated admin functionality. “Zimbra 8.8 is an exciting update for end users and technical decision makers,” said Marcus Teo, Vice President, Enterprise Sales & Marketing, Synacor. “Customers look to Zimbra for security, privacy and transparency through open code, extensibility, accessibility on multiple devices and deployment flexibility. This update builds on these tenets and incorporates enhancemen
GSMA Urges Members of the World Trade Organization to Prioritise and Accelerate Investment in Digital Future13.12.2017 12:00 | Pressemelding
On the occasion of the 11th World Trade Organization (WTO) Ministerial Conference, GSMA Director General Mats Granryd called on government leaders to reform their regulatory frameworks in order to encourage a new wave of innovation and investment in digital infrastructure and services. Currently, 108 of the WTO's 164 members have made commitments to facilitate trade in telecoms services, such as the right to establish new telecoms companies, make foreign direct investment in existing companies and enable the cross-border transmission of telecoms services. “Today, more than 5.1 billion people – about two-thirds of the world’s population – subscribe to mobile services. With this broad reach, the mobile industry is a major driver in the global economy, expected to employ nearly 31 million people worldwide and contribute $4.2 trillion in economic value (4.9 per cent of GDP) in 2020,” said
DCS Telecom Selects LeoSat for Innovative Data Solution13.12.2017 10:03 | Pressemelding
LeoSat Enterprises, which is launching a constellation of up to 108 low-earth-orbit communications satellites, has entered into an agreement with DCS Telecom, a leading telecoms provider of satellite and networking solutions in the Middle East, Africa and Asia. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213005443/en/ DCS Telecom Selects LeoSat for Innovative Data Solution (Photo: Business Wire) DCS Telecom will use LeoSat to upgrade its existing satellite solutions, giving customers access to a unique low-latency network which is expected to revolutionize data connectivity. LeoSat’s system of low earth orbit communications satellites can achieve lower latency and stronger end-to-end security compared to traditional satellite and terrestrial solutions used today. This is achieved through an adv
Andersen Global Expands Presence in Germany with Addition of Thierhoff Müller & Partner13.12.2017 08:01 | Pressemelding
Andersen Global is proud to announce an expanded presence in Germany as Thierhoff Müller & Partner, a tax and legal firm with offices in Leipzig and Frankfurt, combines its practice with Andersen Tax & Legal in Germany. Through its German member firms, Andersen Tax & Legal and Alegis Steuerberatungsgesellschaft mbH, Andersen Global now has more than 65 professionals focused on providing tax and legal services and business advice across five locations in Germany, including Cologne, Dusseldorf, and Merzig. “Thierhoff Müller is highly regarded in complex restructuring matters. Together with our existing legal and tax practice, we will be able to increase our service offerings for our clients,” said Stefan Kraus, Managing Partner of Andersen Tax & Legal in Germany. “We are dedicated to providing outstanding service and are adding additional competencies in tax and legal such as corporate r
Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs13.12.2017 08:00 | Pressemelding
Aprecia Pharmaceuticals, LLC (“Aprecia”), The 3DP Pharmaceutical Company, and Cycle Pharmaceuticals, Ltd. (“Cycle”) today announced they have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (“3DP”) technology. The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose® Technology platform. ZipDose® is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration. Antonio Benedetti, CEO of Cycle commented: “Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations. Aprecia’s
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom